Elif Karabacak

Dr. Elif Karabacak

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2024 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
EKElif Karabacak
Elif Karabacak
HEHazal Eken
Hazal Eken
Ilhem DallaliIlhem Dallali
Ilhem Dallali
RARana Arslan
Rana Arslan
We purposed to explore the consequences of the use quercetin and fisetin alone and in combination with pregabalin and gabapentin, which are used in the management of neuropathic pain, and on neuropathic pain in general. The anti-allodynic effect of various doses (5, 10, and 20 mg/kg) of quercetin and fisetin, both singly and in combination with pregabalin and gabapentin, was evaluated by developing a neuropathic pain model induced by chronic constrictive nerve damage in rats. The effectiveness of these flavonoids was investigated by combining them with gabapentin (50 mg/kg) and pregabalin (15 mg/kg), choosing the effectual dose of 10 mg/kg and the dose of 5 mg/kg, which did not show significant antiallodynic effects. In groups combined with gabapentin and pregabalin, it was determined that they showed a significant antiallodynic effect compared with 50 mg/kg gabapentin and 15 mg/kg pregabalin. In conclusion, in our combination studies, it was observed that the effectiveness of gabapentin and pregabalin, was increased and the duration of effect was prolonged when used with lower doses of flavonoids. Based on these findings; it is possible to say that quercetin and fisetin are potential agents that can be used alone or in combination with other effective treatments to alleviate neuropathic pain.

9 June 2026 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
EKElif Karabacak
Elif Karabacak
MYMuhtesem E. Yayla
Muhtesem E. Yayla
GOGulsah Y. Ozturk
Gulsah Y. Ozturk
BOBahadir Ozelbaykal
Bahadir Ozelbaykal
Fibromyalgia (FM) is a chronic, widespread musculoskeletal disease that is usually accompanied by hyperalgesia, fatigue, sleep disturbance and depression. Although the etiopathogenesis of this syndrome is unclear, it is presumed to have an inflammatory basis. There are currently no laboratory markers available to diagnose the condition. The aim of this study was to investigate potential biochemical markers that would prove to be valid, simple, routinely used, quickly and cheaply studied and obtainable in blood count tests. 46 patients diagnosed with FM according to ACR (American College of Rheumatology) 2010 diagnostic criteria and 35 patients as a healthy control group were included in the study. Prealbumin, complete blood count, sediment and C-reactive protein (CRP) values of FM and control group patients were examined. Additionally, Hospital Anxiety and Depression Scale, Jenkins Sleep Scale and the Fibromyalgia Impact Questionnaire (FIQ) were administered to patients diagnosed with FM. There was a significant difference between fibromyalgia patients and control groups in terms of prealbumin, platelet, CRP, CRP/prealbumin and lymphocyte parameters (P=0.048, P=0.046, P<0.001, P=0.003 and P<0.001, respectively). Only a weak positive correlation was found between CRP and FIQ (rS =0.309, P=0.037, CI=0.012-0.556). The serum levels of some tested markers, including platelets, CRP, CRP/prealbumin and lymphocytes, were significantly higher and prealbumin was lower in patients with FM than in the control group, suggesting they could be valid in fibromyalgia diagnosis. The CRP level may be informative about the severity of the FM and it may play a role in the inflammation possibly underlying the pathogenesis of FM.

27 April 2026 in International Journal of Traditional and Complementary Medicine Research
Verified
Journal Article
Closed access
ÖAÖzgür Akbey
Özgür Akbey
EKElif Karabacak
Elif Karabacak
EYEmir Enis Yurdgülü
Emir Enis Yurdgülü
YBYasin Bayır
Yasin Bayır
Aim: The use of isotretinoin (ISOT) is known as the last step in treatment due to its side effects on the kidneys and other organs. The aim of this study was to evaluate the protective effect of curcumin-rich turmeric extract (CRTE) against kidney damage caused by isotretinoin based on oxidative stress parameters and routine biochemical parameters indicating kidney damage.Material and Methods: Weighing 220-240 gr gavage to rats for 30 days, the treatment groups and the control group dissolved in sunflower oil ISOT 7.5 mg/kg/day ISOT 50, 100, 200 mg/kg/day extract of turmeric from rich kurkumi was performed. after 30 days, the mice were anesthetized, and then kidney tissues and blood were taken. The experiment was terminated by euthanasia. Finally, BUN and CRT levels of the blood and SOD, GSH and MDA levels in the kidney tissue were determined.Results: At the end of the study, BUN, CRT levels and kidney MDA levels increased and SOD and GSH levels decreased in the isotretinoin group compared to the healthy control group. (CRTE+ISOT) in the 50, 100 and 200 mg/kg/day groups, on the other hand, showed a statistically BUN, CRT and SOD, GSH and MDA levels, especially in the group with 200 mg/kg/day at all three doses. There was no difference in the groups given CRTE and sunflower oil.Conclusion: The protective effect of curcumin-rich turmeric extract in eliminating the side effects of kidney damage caused by isotretinoin therapy may suggest it as a herbal medicine.

4 June 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
SCSerkan Cerrah
Serkan Cerrah
ABAhmed Ramiz Baykan
Ahmed Ramiz Baykan
ESEsra Tuba Sezgin
Esra Tuba Sezgin
GHGulbaniz Huseynova
Gulbaniz Huseynova
EKElif Karabacak
Elif Karabacak
HSHalis Suleyman
Halis Suleyman
Objective: Linezolid (LZD), an oxazolidinone antibiotic widely used against Gram-positive infections, has been associated with mitochondrial dysfunction and hepatotoxicity, particularly during prolonged use. This study aimed to investigate the protective effects of adenosine triphosphate (ATP) and Liv-52 against LZD-induced liver injury, with a focus on oxidative stress, inflammation, and necroptosis pathways. Methods: Twenty-four male Wistar rats were randomly assigned to four groups: healthy control (HG), LZD-treated (LZDG), Liv-52 + LZD (LVLZ), and ATP + LZD (ATLZ). Liv-52 (50 mg/kg, orally) and ATP (5 mg/kg, intraperitoneally) were administered prior to LZD (125 mg/kg, orally) for 14 days. Results: Following LZD administration, malondialdehyde (MDA) levels markedly increased, indicating oxidative stress, while total glutathione (tGSH), superoxide dismutase (SOD), and catalase (CAT) activities significantly decreased. Histopathological examination revealed pronounced hepatocellular damage accompanied by increased NF-κB, NLRP3, RIPK3, and MLKL expression, indicating activation of inflammatory and necroptotic pathways. Treatment with ATP and Liv-52 significantly ameliorated these biochemical, histopathological, and molecular alterations. Conclusions: Treatment with ATP and Liv-52 significantly attenuated oxidative stress, improved histopathological alterations, and suppressed the expression of inflammatory and necroptotic markers. Notably, ATP exhibited a more pronounced protective effect compared to Liv-52. In conclusion, LZD induces hepatotoxicity through oxidative stress-mediated inflammatory and necroptotic mechanisms, while ATP and Liv-52 confer hepatoprotection, with ATP showing superior efficacy.

3 April 2026
Verified
Book Chapter
Closed access
EKElif Karabacak
Elif Karabacak
Parkinson hastalığı (PD), geniş bir motor ve motor dışı semptom yelpazesiyle karakterize olan ilerleyici bir nörodejeneratif bozukluktur ve mevcut tedavi yaklaşımları yalnızca semptomatik iyileşme sağlamakta, hastalığın ilerleyişini değiştirememektedir. Son yıllarda PD’nin mekanistik temellerini aydınlatmak ve potansiyel terapötik müdahaleleri değerlendirmek amacıyla çok sayıda hayvan modeli geliştirilmiştir. Bu modeller; farmakolojik ajanlar, nörotoksinler, pestisitler, genetik manipülasyonlar, α-sinüklein aşılaması ve viral vektör aracılı gen aktarımı gibi çeşitli yöntemlerle oluşturulmaktadır. Her ne kadar hiçbir model PD’nin tam klinik ve patolojik özelliklerini bütünüyle yeniden oluşturamasa da, motor ve motor dışı fenotiplerin belirli yönlerini taklit ederek hastalığın biyolojik mekanizmalarına ilişkin kritik bilgiler sağlamaktadırlar. Kemirgenler, insan dışı primatlar ve Drosophila melanogaster ile Caenorhabditis elegans gibi memeli olmayan organizmalar dahil olmak üzere geniş bir tür yelpazesinde geliştirilen bu modeller, hem klasik hem de daha az çalışılmış deneysel paradigmaları kapsamaktadır. Ayrıca, bu modeller PD’nin birincil patojenik özelliklerinin yanı sıra mitokondriyal bozulma, otofajik disfonksiyon ve nöroinflamasyon gibi ikincil patolojik süreçlerin incelenmesine de olanak tanımaktadır. Bu derleme, Parkinson hastalığı araştırmalarında kullanılan geleneksel ve geleneksel olmayan hayvan modellerine ilişkin kapsamlı ve güncel bir genel bakış sunmayı ve araştırmacıların kendi bilimsel sorularına en uygun modeli seçmelerine rehberlik etmeyi amaçlamaktadır. Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by a wide spectrum of motor and non-motor symptoms, and current therapeutic approaches remain limited to symptomatic relief without modifying disease progression. Over recent decades, numerous animal models have been developed to elucidate the mechanistic basis of PD and to evaluate potential therapeutic interventions. These models are generated through pharmacological agents, neurotoxins, pesticides, genetic manipulations, α-synuclein inoculation, and viral vector–mediated gene delivery. Although none of these models fully recapitulates the complete pathological and clinical profile of PD, they successfully mimic distinct motor and non-motor phenotypes, thereby providing critical insights into disease mechanisms. A broad range of species—including rodents, non-human primates, and non-mammalian organisms such as Drosophila melanogaster and Caenorhabditis elegans—have been utilized, encompassing both well-established and underexplored experimental paradigms. In addition to replicating primary pathogenic features, these models permit the investigation of secondary pathological processes such as mitochondrial impairment, autophagic dysfunction, and neuroinflammation. This review aims to offer a comprehensive and up-to-date overview of conventional and unconventional PD animal models and to guide researchers in selecting the most appropriate model tailored to their specific scientific objectives.

28 August 2024 in Turkish Journal of Biochemistry
Verified
Journal Article
Open access
PDF file
KYKanay Yararbas
Kanay Yararbas
CSCeyhan Sayar
Ceyhan Sayar
CTCemre Tavukcu
Cemre Tavukcu
TKTaner Korkmaz
Taner Korkmaz
DÇDilara Çakmak Çankaya
Dilara Çakmak Çankaya
UOUgur Ozbek
Ugur Ozbek
Objectives: BLM , a member of the RecQ helicase family, plays an important role in DNA repair, and its biallelic mutations cause autosomal recessive Bloom syndrome, a disease characterized by elevated levels of sister chromatid exchange (SCE) in affected individuals and hereditary cancer susceptibility in carriers. This study aims to investigate genomic instability in breast cancer patients carrying heterozygous variants in the BLM gene. Methods: Spontaneous chromosome breakage count and SCE counting were performed on newly drawn blood cultures, both spontaneous and stimulated. The spontaneous breakage count was conducted alongside control samples. In SCE analysis, 0–10 per metaphase was considered normal, 10–40 borderline, and counts above 40 were considered high. Results: The study included 26 patients and one healthy control at each session. The clinical and pathological characteristics of the patients were evaluated. The analyses revealed borderline-level increased SCE rates in only one patient. No increase in spontaneous breakage count or SCE analysis was observed in other individuals compared to controls. Conclusions: Increased genomic instability was not observed in the analyzed patient group. These results can lead to multiple interpretations. The variants carried in the BLM gene in the patient group may be of low pathogenicity, or increased instability compared to controls may not be necessary for heterozygous variants. Additionally, our patient group may not have been exposed to a genotoxic effect causing genomic instability. These results could also indicate a favorable position in terms of avoiding chemotherapy and radiotherapy complications.